A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carcinoma lesions.


Journal

Journal of medical ultrasonics (2001)
ISSN: 1613-2254
Titre abrégé: J Med Ultrason (2001)
Pays: Japan
ID NLM: 101128385

Informations de publication

Date de publication:
Apr 2021
Historique:
received: 19 08 2020
accepted: 24 02 2021
pubmed: 16 3 2021
medline: 6 7 2021
entrez: 15 3 2021
Statut: ppublish

Résumé

By analyzing possible factors contributing to imaging misevaluation of arterial phase (AP) vascularity, we aimed to provide a more proper way to detect AP hypervascularity of hepatocellular carcinomas (HCCs) using the noninvasive imaging modalities magnetic resonance imaging (MRI) and contrast-enhanced ultrasound (CEUS). We retrospectively recruited 164 pathologically confirmed HCC lesions from 128 patients. Using CEUS with Sonazoid (SCEUS) and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid MRI (EOB-MRI), AP vascularity of the lesions was evaluated and inconsistencies in interpretation were examined. Indicators of margin, echogenicity, and halo and mosaic signs of lesions on grayscale US; depth of lesions on SCEUS; and tumoral homogeneity, signal contrast ratio of lesions to the surrounding area on precontrast and AP images on EOB-MRI, and histological grade were investigated. When precontrast images were used to adjust the AP enhancement ratio, the proportion of inconsistent interpretations of AP vascularity declined from 26.2% (43/164; 29 non-hypervascularity instances using EOB-MRI and 14 using SCEUS) to 16.5% (27/164; 7 using EOB-MRI and 20 using SCEUS). Greater lesion depth (P = 0.017), ill-defined tumoral margin (P = 0.028), absence of halo sign (P = 0.034), and histologically early HCC (P = 0.007) on SCEUS, and small size (P = 0.012) and heterogeneity (P = 0.013) of lesions and slight enhancement (low AP enhancement ratio) (P = 0.018 and 0.009 before and after adjustment) on EOB-MRI, may relate to undetectable hypervascularity. SCEUS and EOB-MRI may show discrepancies in evaluating AP vascularity in the case of deep, ill-defined, heterogeneous, slightly enhanced lesions, and histologically early HCCs. We recommend adjusting AP with precontrast images in EOB-MRI, and combining both modalities to detect hypervascularity.

Identifiants

pubmed: 33721130
doi: 10.1007/s10396-021-01086-2
pii: 10.1007/s10396-021-01086-2
doi:

Substances chimiques

Contrast Media 0
Ferric Compounds 0
Oxides 0
Sonazoid 0
gadolinium ethoxybenzyl DTPA 0
Iron E1UOL152H7
Gadolinium DTPA K2I13DR72L

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-224

Références

Kitao A, Zen Y, Matsui O, et al. Hepatocarcinogenesis: Multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography–radiologic-pathologic correlation. Radiology. 2009;252:605–14.
doi: 10.1148/radiol.2522081414
Bartolotta TV, Taibbi A, Midiri M, et al. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography. 2019;38:200–14.
doi: 10.14366/usg.18060
Takahashi M, Maruyama H, Shimada T, et al. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging. Eur J Radiol. 2013;82:75–84.
doi: 10.1016/j.ejrad.2012.05.035
Cassinotto C, Aube C, Dohan A. Diagnosis of hepatocellular carcinoma: an update on international guidelines. Diagn Interv Imaging. 2017;98:379–91.
doi: 10.1016/j.diii.2017.01.014
Kim DK, An C, Chung YE, et al. Hepatobiliary versus extracellular MRI contrast agents in hepatocellular carcinoma detection: hepatobiliary phase features in relation to disease-free survival. Radiology. 2019;293:594–604.
doi: 10.1148/radiol.2019190414
Ishii T, Numata K, Hao Y, et al. Evaluation of hepatocellular carcinoma tumor vascularity using contrast-enhanced ultrasonography as a predictor for local recurrence following radiofrequency ablation. Eur J Radiol. 2017;89:234–41.
doi: 10.1016/j.ejrad.2016.12.018
Mandai M, Koda M, Matono T, et al. Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol. 2011;84:499–507.
doi: 10.1259/bjr/38682601
Numata K, Fukuda H, Miwa H, et al. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma. Eur J Radiol. 2014;83:95–102.
doi: 10.1016/j.ejrad.2013.09.025
Toyota N, Nakamura Y, Hieda M, et al. Diagnostic capability of gadoxetate disodium-enhanced liver MRI for diagnosis of hepatocellular carcinoma: comparison with multi-detector CT. Hiroshima J Med Sci. 2013;62:55–61.
pubmed: 24279123
Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol. 2012;22:1205–13.
doi: 10.1007/s00330-011-2372-3
Burns PN, Wilson SR. Focal liver masses: Enhancement patterns on contrast-enhanced images–concordance of US scans with CT scans and MR images. Radiology. 2007;242:162–74.
doi: 10.1148/radiol.2421051006
Stocker D, Becker AS, Barth BK, et al. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions? Eur Radiol. 2020;30:2922–33.
doi: 10.1007/s00330-019-06596-9
Hennedige T, Yang ZJ, Ong CK, et al. Utility of non-contrast-enhanced CT for improved detection of arterial phase hyperenhancement in hepatocellular carcinoma. Abdom Imaging. 2014;39:1247–54.
doi: 10.1007/s00261-014-0174-1
Kim M, Kang TW, Cha DI, et al. Identification of arterial hyperenhancement in CT and MRI in patients with hepatocellular carcinoma: value of unenhanced images. Korean J Radiol. 2019;20:236–45.
doi: 10.3348/kjr.2018.0339
An C, Park MS, Kim D, et al. Added value of subtraction imaging in detecting arterial enhancement in small (< 3 cm) hepatic nodules on dynamic contrast-enhanced MRI in patients at high risk of hepatocellular carcinoma. Eur Radiol. 2013;23:924–30.
doi: 10.1007/s00330-012-2685-x
Wang F, Numata K, Nihonmatsu H, et al. Application of new ultrasound techniques for focal liver lesions. J Med Ultrason. 2001;2020(47):215–37.
Lyshchik A, Kono Y, Dietrich CF, et al. Contrast-enhanced ultrasound of the liver: technical and lexicon recommendations from the ACR CEUS LI-RADS working group. Abdom Radiol (NY). 2018;43:861–79.
doi: 10.1007/s00261-017-1392-0
Ohama H, Imai Y, Nakashima O, et al. Images of Sonazoid-enhanced ultrasonography in multistep hepatocarcinogenesis: comparison with Gd-EOB-DTPA-enhanced MRI. J Gastroenterol. 2014;49:1081–93.
doi: 10.1007/s00535-013-0859-1
Wang F, Numata K, Nakano M, et al. Diagnostic value of imaging methods in the histological four grading of hepatocellular carcinoma. Diagnostics (Basel). 2020;10:321.
doi: 10.3390/diagnostics10050321
Wilson SR, Kim TK, Jang HJ, et al. Enhancement patterns of focal liver masses: discordance between contrast-enhanced sonography and contrast-enhanced CT and MRI. AJR Am J Roentgenol. 2007;189:W7-12.
doi: 10.2214/AJR.06.1060
Dietrich CF, Averkiou M, Nielsen MB, et al. How to perform contrast-enhanced ultrasound (CEUS). Ultrasound Int Open. 2018;4:E2-15.
doi: 10.1055/s-0043-123931
Greis C. Technical aspects of contrast-enhanced ultrasound (CEUS) examinations: tips and tricks. Clin Hemorheol Microcirc. 2014;58:89–95.
doi: 10.3233/CH-141873
Nihonmatsu H, Numata K, Fukuda H, et al. Low mechanical index contrast mode versus high mechanical index contrast mode: Which is a more sensitive method for detecting Sonazoid microbubbles in the liver of normal subjects? J Med Ultrason. 2001;2016(43):211–7.
Dong Y, Wang WP, Mao F, et al. Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasound. J Gastroenterol Hepatol. 2016;31:822–8.
doi: 10.1111/jgh.13202
Kagawa Y, Okada M, Kumano S, et al. Optimal scanning protocol of arterial dominant phase for hypervascular hepatocellular carcinoma with gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR. J Magn Reson Imaging. 2011;33:864–72.
doi: 10.1002/jmri.22487
Ramalho M, Matos AP, AlObaidy M, et al. Magnetic resonance imaging of the cirrhotic liver: diagnosis of hepatocellular carcinoma and evaluation of response to treatment—part 1. Radiol Bras. 2017;50:38–47.
doi: 10.1590/0100-3984.2015.0132
Kondo F. Histological features of early hepatocellular carcinomas and their developmental process: for daily practical clinical application : hepatocellular carcinoma. Hepatol Int. 2009;3:283–93.
doi: 10.1007/s12072-008-9107-9

Auteurs

Feiqian Wang (F)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.
Ultrasound Department, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.

Kazushi Numata (K)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan. kz-numa@urahp.yokohama-cu.ac.jp.

Makoto Chuma (M)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.

Haruo Miwa (H)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.

Satoshi Moriya (S)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.

Katsuaki Ogushi (K)

Gastroenterological Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Kanagawa, 232-0024, Japan.

Masahiro Okada (M)

Department of Radiology, Nihon University School of Medicine, Tokyo, 173-8610, Japan.

Masako Otani (M)

Division of Diagnostic Pathology, Yokohama City University Medical Center, Kanagawa, 232-0024, Japan.

Yoshiaki Inayama (Y)

Division of Diagnostic Pathology, Yokohama City University Medical Center, Kanagawa, 232-0024, Japan.

Shin Maeda (S)

Division of Gastroenterology, Yokohama City University Graduate School of Medicine, Kanagawa, 236-0004, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH